Arovella Therapeutics Limited Profit Margin

Arovella Therapeutics Limited (ALA.AX) currently reports a profit margin of -1912.44% as of June 2021. That compares with -805.76% in the prior-year period — down 137.3% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Arovella Therapeutics Limited's profit margin history and peer comparisons.

Arovella Therapeutics Limited's profit margin decreased from -805.76% to -1912.44% — a 137.3% year-over-year decrease (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arovella Therapeutics Limited's profit margin of -1912.44% is lower than the Healthcare sector average of 9.48%. That is roughly 20271.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Arovella Therapeutics Limited's current -1912.44% should be judged against Healthcare norms (sector average: 9.48%) and against ALA.AX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1912.44%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Arovella Therapeutics Limited, and consider following ALA.AX for alerts when major investors trade the stock.